|
|
News Breaks | | | | October 2, 2012 | | 08:11 EDT |  | CBLI | Cleveland BioLabs, Incuron announce CBL0102 orphan drug status for CBL0102
Cleveland BioLabs and Incuron, a joint venture between the company and Bioprocess Capital Ventures, announced that curaxin CBL0102 has been granted Orphan Drug status by the U.S. FDA for treatment of hepatocellular carcinoma. A multi-center Phase I trial of CBL0102 is ongoing in the Russian Federation in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma for which standard therapy has failed or does not exist. The trial is dosing the sixth cohort in its dose-escalation arm and, subsequent to the completion of the dose-escalation arm, will enroll an efficacy arm. There are approximately 30,000 U.S. and 45,000 E.U. annual cases of hepatocellular carcinoma, with an overall survival rate of approximately 15%. | |
|
News For CBLI From The Last 14 Days Check below for free stories on CBLI the last two weeks. |
|
|
| May 9, 2013 | | 07:50 EDT |  | CBLI | Cleveland BioLabs reports Q1 EPS (22c), one estimate (17c)
Reports Q1 revenue $1.37M, one estimate $1.73M. | |
|
|
|
|
|
|
